Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Cash from Investing Activities (2017 - 2022)

Historic Cash from Investing Activities for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to $4.4 million.

  • Iterum Therapeutics' Cash from Investing Activities rose 19802.96% to $4.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $14.0 million, marking a year-over-year increase of 12556.46%. This contributed to the annual value of $18.2 million for FY2024, which is 2197.46% down from last year.
  • As of Q4 2022, Iterum Therapeutics' Cash from Investing Activities stood at $4.4 million, which was up 19802.96% from $3.3 million recorded in Q3 2022.
  • Iterum Therapeutics' 5-year Cash from Investing Activities high stood at $35.1 million for Q1 2019, and its period low was -$33.9 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Investing Activities was $25000.0 (2019), whereas its average is -$541411.8.
  • As far as peak fluctuations go, Iterum Therapeutics' Cash from Investing Activities tumbled by 38883.39% in 2018, and later skyrocketed by 5493333.33% in 2021.
  • Iterum Therapeutics' Cash from Investing Activities (Quarter) stood at $28.7 million in 2018, then crashed by 100.01% to -$2000.0 in 2019, then crashed by 350.0% to -$9000.0 in 2020, then tumbled by 49522.22% to -$4.5 million in 2021, then skyrocketed by 198.03% to $4.4 million in 2022.
  • Its Cash from Investing Activities stands at $4.4 million for Q4 2022, versus $3.3 million for Q3 2022 and -$3.3 million for Q2 2022.